UPDATE: Stifel Initiates Coverage On LeMaitre Vascular On Good Investment Opportunity

In a report published Tuesday, Stifel analyst Rick Wise initiated coverage on

with a Buy rating and $11.00 price target. In the report, Stifel noted, “We are initiating coverage of LeMaitre Vascular, Inc. (LMAT) with a Buy rating and $11 target price, reflecting a 2.3x 2015 EV/sales multiple on our $75.7 million estimate. In our view, LeMaitre is a unique and under-appreciated, small-cap medical technology company, offering sustainable high single-digit, top-line growth and an improving profitability outlook. With an experienced, highly disciplined, and dedicated management team (insiders own 34%), we see LeMaitre shares offering a relatively predictable total-return profile, suitable for long-term investors.” LeMaitre Vascular closed on Monday at $7.14.